Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer

Retifanlimab is currently in clinical development for previously untreated metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common lung cancer. There are three main types: adenocarcinoma, squamous cell carcinoma and large-cell lung cancer. Stage IV NSCLC is also called metastatic (the most advanced stage) lung cancer. Smoking tobacco is the cause of most lung cancers and the biggest risk factor. NSCLC is most common in the older population. The main symptoms include a new or prolonged cough, breathlessness, coughing up blood and an ache in the shoulder and chest. Although metastatic NSCLC is considered inoperable and incurable, there are some management options available such as: chemotherapy, immunotherapy and radiation therapy.